Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Declines By 89.4%

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 42,000 shares, a decrease of 89.4% from the October 31st total of 396,100 shares. Based on an average daily volume of 263,800 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Raymond James lowered their price target on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

Institutional Trading of Xilio Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its holdings in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after purchasing an additional 45,554 shares during the last quarter. XTX Topco Ltd bought a new stake in Xilio Therapeutics during the second quarter valued at about $32,000. Finally, Geode Capital Management LLC grew its stake in shares of Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after acquiring an additional 155,337 shares during the last quarter. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Stock Performance

Shares of NASDAQ:XLO opened at $1.01 on Thursday. The stock has a market capitalization of $44.40 million, a price-to-earnings ratio of -0.59 and a beta of -0.24. The company has a 50 day moving average price of $0.93 and a 200 day moving average price of $0.94. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $1.93.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.